Uss Investment Management LTD Seagen Inc. Transaction History

Uss Investment Management LTD

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$191.51 - $216.16 $141,142 - $159,309	737 Added 1.86%	40,284 $8.55 Million
Q2 2023 Aug 14, 2023	BUY	$187.64 - $206.25 $177,507 - $195,112	946 Added 2.45%	39,547 $7.61 Million
Q1 2023 May 12, 2023	BUY	$127.59 - $203.08 $666,147 - $1.06 Million	5,221 Added 15.64%	38,601 $7.82 Million
Q4 2022 Feb 13, 2023	BUY	$117.37 - $139.17 $211,266 - $250,505	1,800 Added 5.7%	33,380 $4.29 Million
Q3 2022 Nov 08, 2022	SELL	$135.27 - $180.11 $360,765 - $480,353	-2,667 Reduced 7.79%	31,580 $4.32 Million

Q2 2022 Aug 12, 2022	SELL	$108.81 - $179.33 $215,770 - $355,611	-1,983 Reduced 5.47%	34,247 $6.06 Million
Q1 2022 May 13, 2022	BUY	$119.61 - $157.85 $421,266 - $555,947	3,522 Added 10.77%	36,230 $5.22 Million
Q3 2021 Nov 15, 2021	BUY	$142.45 - $169.82 $3.21 Million - $3.83 Million	22,531 Added 221.39%	32,708 $5.55 Million
Q4 2020 Feb 12, 2021	BUY	$164.63 - $211.93 $1.68 Million - $2.16 Million	10,177 New	10,177 $1.78 Million

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Uss Investment Management LTD, based on Form 13F filings with the SEC.

Stay updated on Uss Investment Management LTD with notifications on news.